Citizens & Northern Corp Purchases 12,934 Shares of Pfizer Inc. $PFE

Citizens & Northern Corp lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 35.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,935 shares of the biopharmaceutical company’s stock after acquiring an additional 12,934 shares during the quarter. Citizens & Northern Corp’s holdings in Pfizer were worth $1,210,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter worth about $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter worth $35,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The business’s 50 day simple moving average is $24.89 and its two-hundred day simple moving average is $24.13. The stock has a market capitalization of $141.23 billion, a P/E ratio of 13.21, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.